Sylvia F. Boj, Ph.D

Scientific Director

Sylvia F. Boj received her PhD in 2006 at the University of Barcelona, Spain for her work at the Hospital Clinic in the laboratory of Prof. Jorge Ferrer, where she worked on functional genetic analysis to understand the transcriptional role of MODY genes in pancreatic beta cells. With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 regulating metabolism. Then, she established human pancreas organoids from tumor resections in collaboration with the Surgery and Pathology departments from the UMC and the laboratory of Prof. D.A. Tuveson.

In 2014, she started working as a Group Leader at Hubrecht Organoid Technology in Utrecht, the Netherlands. She started leading the Cystic Fibrosis and Pancreatic Cancer Biobank programs. More recently, in 2016, she was appointed as Scientific Director of the HUB, with the ultimate goal of transferring scientific advances of the Organoid Technology to the development of new drugs, by interacting with pharmaceutical companies and developing clinical trials to validate the predictive value of the Organoids for the response of patients to certain treatments.

October 18, 2019 CrownBio launched patient-derived tumor organ... San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development pl... read more
October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more
July 17, 2019 Epistem license Hubrecht Organoid Technology ... Epistem license Hubrecht Organoid Technology to expand preclinical toxicology service portfolio Manchester, 16th July, 2... read more